<DOC>
	<DOCNO>NCT02673710</DOCNO>
	<brief_summary>The purpose study explore relationship sarcopenia , define compute tomography , treatment related outcome body composition related parameter patient population receive bevacizumab beyond progression .</brief_summary>
	<brief_title>A Study Assess Impact Sarcopenia Outcomes Colorectal Cancer Survivors Treated With Chemotherapy Combined With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sarcopenia</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; = 18 year Participants treat first line bevacizumab decide continue treatment Bevacizumab beyond first progression Participants Metastatic Colorectal Cancer ( mCRC ) comply beyond Progressive Disease ( PD1 ) reimbursement criterion Women childbearing potential use effective contraception ( 6 month ) treatment . Availability specific retrospective data diagnosis 1st line treatment Participants receive 1st line still participate clinical trial study exception participation registry trial Dementia another mental condition make impossible fill questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>